



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

The need for a global COVID-19 maternal immunisation research plan



Published Online
January 25, 2021
[https://doi.org/10.1016/S0140-6736\(21\)00146-X](https://doi.org/10.1016/S0140-6736(21)00146-X)

There is evidence that COVID-19 threatens maternal and perinatal health. Pregnant women, especially in the second half of pregnancy, are at increased risk of complications—eg, severe pneumonia, hospitalisations, admission to intensive care unit, invasive mechanical ventilation—and death from COVID-19 compared with age-matched non-pregnant women.^{1,3} Existing evidence also suggests that pregnant women with COVID-19 are at higher risk of having a preterm delivery and that their neonates are three times more likely to be admitted to hospital than those born to mothers without COVID-19.^{4,5}

Pregnant women are not recognised as a high-priority group for COVID-19 vaccination, despite the risk of complications and poor perinatal outcomes.⁶ Pregnant women were excluded from early COVID-19 vaccine research, resulting in a missed opportunity to generate safety and efficacy data, and potentially affecting whether pregnant women will receive the benefits of COVID-19 vaccines.

Reasonably, safety knowledge gaps lead vaccine developers to systematically exclude pregnant women from early clinical studies. However, preclinical and clinical data suggest an acceptable safety profile for most COVID-19 vaccines in development.⁷⁻⁹ Furthermore, after emergency use authorisation for COVID-19 vaccines by the US Food and Drug Administration and support from the US Centers for Disease Control and Prevention¹⁰ and the American College of Obstetricians and Gynecologists,¹¹ and a similar stance from the UK Joint Committee on Vaccination and Immunisation,¹² a substantial number of pregnant and lactating women are likely to be vaccinated if they also belong in high-priority risk groups for vaccination.

There is an urgent need for a proactive, global COVID-19 immunisation plan for the evaluation of COVID-19 vaccines in pregnant women in clinical trials before and after COVID-19 vaccine allocation. This plan should be based on a clear understanding of the effects of COVID-19 on pregnant women, the fetus, and the newborn baby (risks of the disease), as well as of the safety profile of COVID-19 vaccines (risks of the vaccine) and their efficacy. Such knowledge is needed for risk-benefit analyses to inform COVID-19 vaccine trials in

pregnancy and the use of COVID-19 vaccines in pregnant women before and after regulatory approvals. The use of an approved vaccine in pregnant women needs to be supported by a favourable balance between the benefit and minimum risk for the mother and fetus, in the context of this pandemic. The collection of specific safety data in pregnancy is crucial to enable pregnant women and health-care providers to make informed decisions.

The criteria to be met by COVID-19 vaccine candidates for their evaluation and use in pregnancy need to be clearly defined. These criteria could include the completion of developmental and reproductive toxicology studies in appropriate animal models, and ascertainment of an acceptable reactogenicity profile with a low incidence of maternal fever after vaccination. Obtaining safety data in pregnancy is of particular relevance given the novelty of some of the COVID-19 vaccine platforms and adjuvants. Research protocols should include comprehensive and rigorous monitoring of maternal, perinatal, and infant safety endpoints, given the potential for obstetric and perinatal events and possible perception of an association with the vaccination. Immunogenicity information relevant to pregnancy is necessary, including documenting the immune response during pregnancy and the passage of vaccine-induced antibodies through the placenta and breastmilk, given the potential for infant protection through maternal immunisation.¹³ Understanding the



impact of maternal infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different trimesters of gestation would help determine the optimal timing of vaccination to protect the pregnant mother from severe COVID-19 and its complications.

The perspectives of low-income and middle-income countries (LMICs) are also important for the evaluation and implementation of COVID-19 vaccines in pregnancy. COVID-19 cases and deaths in southeast Asia, Central and South America, and, to some extent, Africa¹⁴ contribute a meaningful proportion of the global confirmed COVID-19 cases and deaths. The inclusion of pregnant women from LMICs in COVID-19 vaccine research is of relevance not only for individual benefit but also for overall societal benefit, because women of reproductive age are represented in essential groups in LMICs—eg, health-care providers, carers of children, and the workforce.

Globally, there are more than 213 million pregnancies every year, of which an estimated 190 million (89%) occur in low-resource settings,¹⁵ where the risks of poor obstetric and perinatal outcomes are highest. The inclusion of pregnant women in COVID-19 vaccine research plans is imperative to provide informed, fair, and equitable opportunities for all pregnant women and their infants, and maximise the impact of COVID-19 vaccines worldwide.

FMM reports personal fees as a collaborator of SPEAC (Safety Platform for Emergency vACcines project) of the Coalition for Epidemic Preparedness Innovations, personal fees as a member of the Data Safety Monitoring Board for Moderna's vaccines (pandemic influenza, Zika virus, Chikungunya, CMV, RSV, HMPV-PIV, SARS-CoV-2), and non-financial support as unpaid Co-chair of the COVAX Maternal Immunization Working Group. CC is a subinvestigator on COVID-19 vaccine trials sponsored by Oxford-AstraZeneca and by Novavax for their sites in South Africa. ES is an unpaid member of the COVAX Maternal Immunization Working Group. AB, SBO, CM, and TA declare no competing interests.

*Azucena Bardají, Esperança Sevene, Clare Cutland, Clara Menéndez, Saad B Omer, Teresa Aguado, Flor M Muñoz

azucena.bardaji@isglobal.org

ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Barcelona, Spain (AB, CM, TA); Manhiça Health Research Centre, Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique (AB, ES, CM); Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain (AB, CM); Department of Physiological Sciences, Clinical Pharmacology, Faculdade de Medicina, Universidade Eduardo Mondlane,

Maputo, Mozambique (ES); African Leadership in Vaccinology Expertise (ALIVE), Faculty of Health Sciences, University of the Witwatersrand, Parktown, Johannesburg, South Africa (CC); Yale Institute for Global Health, Department of Internal Medicine, Yale School of Medicine, Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale School of Nursing, New Haven, CT, USA (SBO); Department of Pediatrics and Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA (FMM)

- 1 Pirjani R, Hosseini R, Soori T, et al. Maternal and neonatal outcomes in COVID-19 infected pregnancies: a prospective cohort study. *J Travel Med* 2020; **27**: taaa158.
- 2 Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–October 3, 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**: 1641–47.
- 3 Ellington S, Strid P, Tong VT, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–June 7, 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**: 769–75.
- 4 Woodworth KR, Olsen EO, Neelam V, et al. Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy—SET-NET, 16 Jurisdictions, March 29–October 14, 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**: 1635–40.
- 5 Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ* 2020; **370**: m3320.
- 6 WHO. SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply. Version 1.1. Nov 13, 2020. Geneva: World Health Organization, 2020.
- 7 Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med* 2020; published online Dec 30. <https://doi.org/10.1056/NEJMoa2035389>.
- 8 Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 2020; **383**: 2603–15.
- 9 Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021; **397**: 99–111.
- 10 US Centers for Disease Control and Prevention. Vaccination considerations for people who are pregnant or breastfeeding. Jan 7, 2021. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html> (accessed Jan 19, 2021).
- 11 American College of Obstetricians and Gynecologists. Vaccinating pregnant and lactating patients against COVID-19. Dec 21, 2020. <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-against-covid-19> (accessed Jan 19, 2021).
- 12 JCVI. Joint Committee on Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination. Dec 30, 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/950113/jcvi-advice-on-priority-groups-for-covid-19-vaccination-30-dec-2020-revised.pdf (accessed Jan 19, 2021).
- 13 Edlow AG, Li JZ, Collier AY, et al. Assessment of maternal and neonatal SARS-CoV-2 viral load, transplacental antibody transfer, and placental pathology in pregnancies during the COVID-19 pandemic. *JAMA Netw Open* 2020; **3**: e2030455.
- 14 WHO. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. Jan 12, 2021. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports> (accessed Jan 15, 2021).
- 15 Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. *Stud Fam Plann* 2014; **45**: 301–14.